[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100446003":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":25,"locations":18,"responsibleParty":31,"collaborators":33,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":46,"sex":52,"minAge":53,"maxAge":18,"enrollmentInfo":54,"targetDuration":18,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":18,"overallStatus":64,"whyStopped":18,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":18},{"fullName":5,"class":6},"University Hospital, Essen","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention:","EXPERIMENTAL","Complex, technology supported survivorship intervention using wearable devices for patients, supportive patient apps and physician apps for risk prediction. Increased Cardio-oncology visits assigned to risk patients as predicted by the app.",[13],"Combination Product: Technology supported, coordinated survivorship care using wearable devices, supportive patient-apps and cardio-oncology physician apps",{"label":15,"type":16,"description":17,"interventionNames":18},"Control arm:","NO_INTERVENTION","Wearable device for patients together with a basic patient app providing feedback on the wearable device records and patient information material.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"COMBINATION_PRODUCT","Technology supported, coordinated survivorship care using wearable devices, supportive patient-apps and cardio-oncology physician apps","Patient-centered, technology-supported integrated survivorship- and care management",[9],[26],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},"Norbert Graf, MD","CONTACT","+49- 6841\u002F16-28397","norbert.graf@uks.eu",{"type":32,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[34,36,38,40,42],{"name":35,"class":6},"Universität des Saarlandes",{"name":37,"class":6},"Institut Paoli-Calmettes",{"name":39,"class":6},"Medical University of Warsaw",{"name":41,"class":6},"University Of Perugia",{"name":43,"class":6},"Centre for Research and Technology Hellas","100446003","allolife---life-after-transplantation-100446003",false,"NCT05087784","AlloLife - Life After Transplantation","AlloLife - Life After Allogeneic Hematopoietic Stem Cell Transplantation","AlloLife","Inclusion Criteria:\n\n* Age \\> 18\n* Patients with performed allogeneic stem cell transplantation any type of donor, stem cell source, GVHD prophylaxis or conditioning regimen and at least at day +20 after HCT.\n* Hematologic Remission after HCT at study entrance, MRD positive patients are allowed to enter the study\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-3\n* Signature of informed and written consent by the subject or by the subject's legally acceptable representative for patients under guardianship or trusteeship to participate in the study\n* Access to an internet connected device (smartphone\u002Ftablet\u002Fcomputer)\n* Able to understand and communicate in the respective language\n* Consent to use a wearable device through the time of the study\n* Consent to use a chatbot application for both healthcare data exchange and psychologic intervention\n\nExclusion Criteria:\n\n* Missing consent to use a wearable device and contribute personal data collected at the point of life to the study\n* ECOG performance status of 4\n* Relapse of the disease at study inclusion\n* Uncontrolled systemic infection\n* Diagnosis of a secondary malignancy requiring systemic therapy\n* Reported ongoing severe depression or potential suicidal ideation\n* Vulnerable patients such as: minor, persons deprived of liberty, persons in Intensive Care Unit unable to provided informed consent prior to the intervention\n* Other ongoing interventional protocol that might interfere with the current study primary endpoint","ALL","18 Years",{"count":55,"type":56},192,"ESTIMATED","INTERVENTIONAL",[59],"NA","Survivors of allo HCT can experience long-term survival, which is however limited by a number of late effects. These will be addressed in AlloLife to improve quality of life (QoL) and survival.",[62,63],"Survivorship","Stem Cell Transplant Complications","NOT_YET_RECRUITING","2021-11-08",{"date":67,"type":68},"2021-11-16","ACTUAL",{"date":70,"type":56},"2024-03",{"date":72,"type":56},"2026-06",{"name":5,"class":6}]